Cliff Asness's LXEO Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 337,386 shares of Lexeo Therapeutics, Inc. (LXEO) worth $3.35 M, representing 0.00% of the portfolio. First purchased in 2024-Q4, this short-term holding has been held for 5 quarters.
Based on 13F filings, Cliff Asness has maintained this position in LXEO for several quarters, showing initial confidence in the investment. Largest addition occurred in Q3 2025, adding 159,288 shares. Largest reduction occurred in Q4 2025, reducing 10,537 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Lexeo Therapeutics (LXEO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Lexeo Therapeutics (LXEO) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -10,537 | Reduce 3.03% | 337,386 | $9.93 |
| Q3 2025 | +159,288 | Add 84.44% | 347,923 | $6.64 |
| Q2 2025 | +138,298 | Add 274.74% | 188,635 | $4.02 |
| Q1 2025 | +39,627 | Add 370.00% | 50,337 | $3.47 |
| Q4 2024 | +10,710 | New Buy | 10,710 | $6.58 |
Cliff Asness's Lexeo Therapeutics Investment FAQs
Cliff Asness first purchased Lexeo Therapeutics, Inc. (LXEO) in Q4 2024, acquiring 10,710 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Lexeo Therapeutics, Inc. (LXEO) for 5 quarters since Q4 2024.
Cliff Asness's largest addition to Lexeo Therapeutics, Inc. (LXEO) was in Q3 2025, adding 347,923 shares worth $2.31 M.
According to the latest 13F filing for Q4 2025, Cliff Asness's firm, Aqr Capital Management LLC, owns 337,386 shares of Lexeo Therapeutics, Inc. (LXEO), valued at approximately $3.35 M.
As of the Q4 2025 filing, Lexeo Therapeutics, Inc. (LXEO) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Lexeo Therapeutics, Inc. (LXEO) was 347,923 shares, as reported at the end of Q3 2025.